Citations

Showing 10 of 108135 citations.

Current state of educational compensation in academic neurology
Sarva, Harini , Weaver, Joshua, Wang, Fei , Chou, Jingyuan, Cornes, Susannah , Nickels, Katherine , Poncelet, Ann , Stern, Barney J. , Weber, Daniel , Safdieh, Joseph E. , Nickels, Katherine C , Weber, Daniel J. , Weaver, Joshua

Mayo Clinic

Neurology | May 18, 2019 | Volume: 93 | Issue: 1 | Pages: 30-34

10.1212/wnl.0000000000007664 | PMID 31101740 Get It

CAR T‐cells: Driving in the Fast Lane
Ansell, Stephen M. , Corradini, Paolo

Mayo Clinic

HemaSphere | May 17, 2019 | Volume: 3 | Issue: 3 | Pages: No page available

10.1097/hs9.0000000000000209 | PMID 31723836 Get It

Association Between Critical Care Admissions and Cognitive Trajectories in Older Adults*
Schulte, Phillip J. , Martin, David P. , Deljou, Atousa , Petersen, Ronald C. , Hanson, Andrew C. , Schroeder, Darrell R. , Schroeder, Darrell , Warner, David O. , Mielke, Michelle M. , Knopman, David S. , Weingarten, Toby N. , Warner, Matthew A. , Rabinstein, Alejandro A. , Šprung, Juraj

Mayo Clinic

Critical Care Medicine | May 17, 2019 | Volume: 47 | Issue: 8 | Pages: 1116-1124

10.1097/ccm.0000000000003829 | PMID 31107280 Get It

Objectives: Patients requiring admission to an ICU may subsequently experience cognitive decline. Our objective was to investigate longitudinal cognitive trajectories in older adults hospitalized in ICUs. We hypothesized that individuals hospitalized for critical illness develop greater cognitive decline compared with those who do not require ICU admission. Design: A retrospective cohort study using prospectively collected cognitive scores of participants enrolled in the Mayo Clinic Study of Aging and ICU admissions retrospectively ascertained from electronic medical records. A covariate-adjusted linear mixed effects model with random intercepts and slopes assessed the relationship between ICU admissions and the slope of global cognitive z scores and domains scores (memory, attention/executive, visuospatial, and language). Setting: ICU admissions and cognitive scores in the Mayo Clinic Study of Aging from October 1, 2004, to September 11, 2017. Patients: Nondemented participants age 50 through 91 at enrollment in the Mayo Clinic Study of Aging with an initial cognitive assessment and at least one follow-up visit. Interventions: None. Measurements and Main Results: Of 3,673 participants, 372 had at least one ICU admission with median (25–75th percentile) follow-up after first ICU admission of 2.5 years (1.2–4.4 yr). For global cognitive z score, admission to an ICU was associated with greater decline in scores over time compared with participants not requiring ICU admission (difference in annual slope = –0.028; 95% CI, –0.044 to –0.012; p < 0.001). ICU admission was associated with greater declines in memory (–0.029; 95% CI, –0.047 to –0.011; p = 0.002), attention/executive (–0.020; 95% CI, –0.037 to –0.004; p = 0.016), and visuospatial (–0.013; 95% CI, –0.026 to –0.001; p = 0.041) domains. ICU admissions with delirium were associated with greater declines in memory (interaction p = 0.006) and language (interaction p = 0.002) domains than ICU admissions without delirium. Conclusions: In older adults, ICU admission was associated with greater long-term cognitive decline compared with patients without ICU admission. These findings were more pronounced in those who develop delirium while in the ICU.
Continuation of Newly Initiated Midodrine Therapy After Intensive Care and Hospital Discharge: A Single-Center Retrospective Study
Rizvi, Mahrukh, Nei, Andrea M. , Gajić, Ognjen, Mara, Kristin C. , Frazee, Erin N. , Rizvi, Mahrukh S, Mara, Kristin C , Gajic, Ognjen

Mayo Clinic

Critical Care Medicine | May 17, 2019 | Volume: 47 | Issue: 8 | Pages: e648-e653

10.1097/ccm.0000000000003814 | PMID 31107279 Get It

Objectives: Midodrine is an α1-agonist approved for orthostatic hypotension. Recently, it has received attention as an oral vasopressor to facilitate ICU discharge. The purpose of this study was to identify the incidence of continuation of newly initiated midodrine upon ICU and hospital discharge and identify risk factors associated with its occurrence. Design: Single-center retrospective study. Setting: ICU patients from January 2011 to October 2016 at Mayo Clinic, Rochester. Patients: Adult patients admitted to any ICU who received new midodrine for hypotension and survived to discharge. Interventions: None. Measurements and Main Results: During the study period, 1,010 patients were newly started on midodrine and survived to ICU discharge. Midodrine was continued in 67% (672/1,010) of patients at ICU discharge. Admission to cardiovascular surgery ICU and mixed medical/surgical ICU was a risk factor for midodrine continuation at ICU discharge (odds ratio, 3.94 [2.50–6.21] and 2.03 [1.29–3.20], respectively). At hospital discharge, 34% (311/909) of patients were continued on midodrine therapy. History of congestive heart failure predicted midodrine continuation at hospital discharge (odds ratio, 1.49 [1.05–2.12]). Hypertension and use of mechanical ventilation were associated with a decreased odds of midodrine prescription at both ICU and hospital discharge. Of those discharged from the ICU or hospital on midodrine, 50% were concomitantly prescribed antihypertensives. Discharge from the ICU on midodrine was associated with a significantly shorter ICU length of stay (7.5 ± 8.9 vs 10.6 ± 13.4 d) and reduced risk of in-hospital mortality (hazard ratio, 0.47 [95% CI, 0.32–0.70]; p < 0.001), despite no difference in baseline severity of illness scores. In contrast, patients discharged from the hospital on midodrine had a higher risk of 1-year mortality (hazard ratio, 1.60 [95% CI, 1.26–2.04]; p < 0.001). Conclusions: This study established a high prevalence of midodrine continuation in transitions of care. The risks and benefits of this practice remain unclear. Future studies should explore the impact of this practice on patient outcomes and resource utilization. These insights could be used to model interventions for proper tapering, discontinuation, or follow-up of new start midodrine.
Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma
Wu, Xiaosheng , Stenson, Mary, Abeykoon, Jithma P. , Nowakowski, Kevin E., Zhang, Lianwen , Lawson, Joshua D. , Wellik, Linda, Krull, Jordan E. , Wenzl, Kerstin , Novak, Anne J. , Ansell, Stephen M. , Bishop, Gail A. , Billadeau, Daniel D. , Peng, Kah Whye, Schmitt, Daniel M. , Giles, Francis Joseph , Witzig, T.E. , Krull, Jordan E , Lawson, Joshua, Li, Ying , Witzig, Thomas E.

Mayo Clinic

Blood | May 17, 2019 | Volume: 134 | Issue: 4 | Pages: 363-373

10.1182/blood.2018874560 | PMID 31101621 Get It

Abstract Targeting the B-cell receptor and phosphatidylinositol 3-kinase/mTOR signaling pathways has shown meaningful, but incomplete, antitumor activity in lymphoma. Glycogen synthase kinase 3 (GSK3) α and β are 2 homologous and functionally overlapping serine/threonine kinases that phosphorylate multiple protein substrates in several key signaling pathways. To date, no agent targeting GSK3 has been approved for lymphoma therapy. We show that lymphoma cells abundantly express GSK3α and GSK3β compared with normal B and T lymphocytes at the messenger RNA and protein levels. Utilizing a new GSK3 inhibitor 9-ING-41 and by genetic deletion of GSK3α and GSK3β genes using CRISPR/CAS9 knockout, GSK3 was demonstrated to be functionally important to lymphoma cell growth and proliferation. GSK3β binds to centrosomes and microtubules, and lymphoma cells treated with 9-ING-41 become arrested in mitotic prophase, supporting the notion that GSK3β is necessary for the progression of mitosis. By analyzing recently published RNA sequencing data on 234 diffuse large B-cell lymphoma patients, we found that higher expression of GSK3α or GSK3β correlates well with shorter overall survival. These data provide rationale for testing GSK3 inhibitors in lymphoma patient trials.
Superior Labial Artery: Anatomical Considerations
Oliver, Jeremie D. , Huayllani, María T. , Restrepo, David J. , Forte, Antonio J. , Boczar, Daniel , Forte, Antonio Jorge , Huayllani, Maria T , Oliver, Jeremie D , Sisti, Andrea , Nisi, Giuseppe

Mayo Clinic

Aesthetic Surgery Journal | May 17, 2019 | Volume: 39 | Issue: 7 | Pages: NP307-NP308

10.1093/asj/sjz046 | PMID 31100103 Get It

Comparison of Endobronchial Ultrasound–guided Transbronchial Needle Aspiration With Stylet Retracted Partially Versus Completely for Molecular Testing
Fernández-Bussy, Sebastián , Biswas, Abhishek , Labarca, Gonzalo , Jantz, Michael A., Labarca, Gonzalo , Mehta, Hiren J.

Mayo Clinic

Journal of Bronchology & Interventional Pulmonology | May 17, 2019 | Volume: 26 | Issue: 3 | Pages: 222-224

10.1097/lbr.0000000000000596 | PMID 31107296 Get It

Background: Endobronchial ultrasound–guided transbronchial needle aspiration (EBUS-TBNA) is considered to be the initial diagnostic modality for most patients with lung cancer. However, the optimal technique for maximizing yield continues to vary in the real-world setting. Objectives: To evaluate the diagnostic yield of EBUS-TBNA with capillary sampling compared with complete stylet removal for molecular testing. Methods: Retrospective study, data from patients between January to May 2017 with indication of EBUS-TBNA whom ancillary testing, that is, next-generation sequencing, anaplastic lymphoma kinase ( ALK ), and programed death ligand-1 (PD-L1) expression was reviewed. The yield of 2 techniques, stylet retracted halfway (group 1) versus complete retraction (group 2), was compared. Results: A total of 24/27 (88.88%) samples were adequate for next-generation sequencing analysis in group 1 and 21/23 (91.30%) in group 2. For other molecular analyses, 24/27 (88.88%) samples in group 1 and 20/23 (86.95%) samples in group 2 were adequate for ALK analysis. 23/27 (85.18%) samples for group 1 and 20/23 (86.95%) samples for group 2 were adequate for PD-L1 analysis. Positive expression of PD-L1>50% was achieved in 9/23 (39.13%) of group 1 and 5/20 (25%) of group 2. There was no statistical difference in the yield between the 2 groups. Conclusion: EBUS-TBNA using either capillary sampling or complete stylet removal are effective and has a high proportion of satisfactory results for ancillary testing.
A Multicenter Comparison of Complementary and Alternative Medicine (CAM) Discussions in Oncology Care: The Role of Time, Patient-Centeredness, and Practice Context
Tilburt, Jon C. , Yost, Kathleen J. , Lenz, Heinz‐Josef , Zúñiga, María Luisa , O’Byrne, Thomas J., Leppin, Aaron L. , Kimball, Brittany , Fernandez, Cara, Jatoi, Aminah , Barwise, Amelia , Kumbamu, Ashok , Koenig, Barbara A. , Geller, Gail , Roter, Debra , O'Byrne, Thomas, Branda, Megan E. , Kimball, Brittany C , Barwise, Amelia K , Montori, Víctor M. , Larson, Susan Mau

Mayo Clinic

The Oncologist | May 17, 2019 | Volume: 24 | Issue: 11 | Pages: e1180-e1189

10.1634/theoncologist.2019-0093 | PMID 31101701 Get It

Abstract Background Little is known about how complementary and alternative medicine (CAM) is discussed in cancer care across varied settings in the U.S. Methods In two practices affiliated with one academic medical center in southern California (SoCal), and one in the upper Midwest (UM), we audio-recorded patient-clinician interactions in medical oncology outpatient practices. We counted the frequency and duration of CAM-related conversations. We coded recordings using the Roter Interaction Analysis System. We used chi-square tests for bivariate analysis of categorical variables and generalized linear models for continuous variables to examine associations between dialogue characteristics, practice setting, and population characteristics with the occurrence of CAM discussion in each setting followed by multivariate models adjusting for clinician clustering. Results Sixty-one clinicians and 529 patients participated. Sixty-two of 529 (12%) interactions included CAM discussions, with significantly more observed in the SoCal university practice than in the other settings. Visits that included CAM were on average 6 minutes longer, with CAM content lasting an average of 78 seconds. In bivariate tests of association, conversations containing CAM included more psychosocial statements from both clinicians and patients, higher patient-centeredness, more positive patient and clinician affect, and greater patient engagement. In a multivariable model including significant bivariate terms, conversations containing CAM were independently associated with higher patient-centeredness, slightly longer visits, and being at the SoCal university site. Conclusion The frequency of CAM-related discussion in oncology varied substantially across sites. Visits that included CAM discussion were longer and more patient centered. Implications for Practice The Institute of Medicine and the American Society of Clinical Oncology have called for more open discussions of complementary and alternative medicine (CAM). But little is known about the role population characteristics and care contexts may play in the frequency and nature of those discussions. The present data characterizing actual conversations in practice complements a much larger literature based on patient and clinician self-report about CAM disclosure and use. It was found that CAM discussions in academic oncology visits varied significantly by practice context, that the majority were initiated by the patient, and that they may occur more when visit time exists for lifestyle, self-care, and psychosocial concerns.
Comparative Effectiveness of Behavioral Interventions on Quality of Life for Older Adults With Mild Cognitive Impairment
Chandler, Melanie , Fields, Julie A. , Ball, Colleen T. , Phatak, Vaishali , Dean, P.M. , Morris, Miranda , Chandler, Melanie J, Locke, Dona E, Crook, Julia E. , Locke, Dona E.C. , Dean, Pamela M., Smith, Glenn E.

Mayo Clinic

JAMA Network Open | May 17, 2019 | Volume: 2 | Issue: 5 | Pages: e193016

10.1001/jamanetworkopen.2019.3016 | PMID 31099860 Get It

Regulostat Inferelator: a novel network biology platform to uncover molecular devices that predetermine cellular response phenotypes
Ung, Choong Yong , Bari, Mehrab Ghanat, Zhang, Cheng , Correia, Cristina , Ghanat Bari, Mehrab, Correia, Cristina , Liang, Jingjing , Li, Hu

Mayo Clinic

Nucleic Acids Research | May 17, 2019 | Volume: 47 | Issue: 14 | Pages: e82-e82

10.1093/nar/gkz417 | PMID 31114928 Get It

Abstract With the emergence of genome editing technologies and synthetic biology, it is now possible to engineer genetic circuits driving a cell's phenotypic response to a stressor. However, capturing a continuous response, rather than simply a binary ‘on’ or ‘off’ response, remains a bioengineering challenge. No tools currently exist to identify gene candidates responsible for predetermining and fine-tuning cell response phenotypes. To address this gap, we devised a novel Regulostat Inferelator (RSI) algorithm to decipher intrinsic molecular devices or networks that predetermine cellular phenotypic responses. The RSI algorithm is designed to extract gene expression patterns from basal transcriptomic data in order to identify ‘regulostat’ constituent gene pairs, which exhibit rheostat-like mode-of-cooperation capable of fine-tuning cellular response. Our proof-of-concept study provides computational evidence for the existence of regulostats and that these networks predetermine cellular response prior to exposure to a stressor or drug. In addition, our work, for the first time, provides evidence of context-specific, drug–regulostat interactions in predetermining drug response phenotypes in cancer cells. Given RSI-inferred regulostat networks offer insights for prioritizing gene candidates capable of rendering a resistant phenotype sensitive to a given drug, we envision that this tool will be of great value in bioengineering and medicine.